Date de l'évènement: Thursday, 9 July, 2020 to Sunday, 28 February, 2021
Christophe Chevillard is editor of a special issue of International Journal of Molecular Sciences (ISSN 1422-0067) on "Genetic Analysis, Pathogenic Process Deciphering, Drug Development in Parasitic Diseases".
Interests: Cardiac & Cardiovascular Systems; Parasitology; Genomics; Schistosomiasis; human susceptibility to infection and severe disease.
Deadline for manuscript submissions: February 28th 2021.
Dear Colleagues, Infectious diseases still affect the health of many people today. The morbidity and mortality rates associated with these diseases are considerable. However, it is now recognized that these infections particularly affect some individuals while sparing others. Significant progresses have been made in recent years for each of these diseases. These important changes essentially concern: Patient management (new methods for diagnosis based on molecular biology tests); Genetic analysis (case controls studies, whole genome analysis, linkage analysis exome sequencing, variant enrichment analysis); Identification of susceptible loci, which is an important step in the knowledge of these diseases but is essential to characterize the functional impact of these variants with methods such as those linked to crispr/cas9 technology; Deciphering the pathogenic processes (single -omic and multiple -omic approaches and high-throughput sequencing strategies). Indeed, -omic approaches provide a full set of data which are useful in exploring the pathogenic process. However, the analysis of an -omic approach does not provide a complete overview of biological systems. Recently, many tools have been developed to study all these -omics together. The data from the different -omics will be grouped into groups of data with similar behavior, and then an auto-encoder will be used to keep only the groups that allow phenotype prediction of the individuals; Identification and characterization of biomarkers that can be used for diagnosis as well as prognosis tests (biomarker set development based on OMIC results, machine learning etc.); Development of new drugs, exhaustive studies on the efficacy of old and/or new drugs or drug cocktails. The submission of original research articles or up-to-date review articles, and commentaries related to these (non-exhaustive) topics is encouraged. Dr. Christophe Chevillard Guest Editor